Revenue: Up 18% in the six months ended September 30 to $951.2 million.
Net profit after tax: Up 43% to $153.2m.
Main takeaway: The listed respiratory healthcare company will not be drawn on the potential impact of US tariffs on Mexico, where the company has a large manufacturing facility.
The boss of Fisher & Paykel Healthcare has refused to be drawn into any speculation on the possible impact of United States President-elect Donald Trump vowing to impose a 25% tariff on all products coming from Mexico.
The listed respiratory healthcare company today reported record half-year revenue
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly
credit card debit
Revenue: Up 18% in the six months ended September 30 to $951.2 million.
Net profit after tax: Up 43% to $153.2m.
Main takeaway: The listed respiratory healthcare company will not be drawn on the potential impact of US tariffs on Mexico, where the company has a large manufacturing facility.
